Interview with: Renaud Beauchesne, President and CEO - featuring: their Dermylex product that is a mix of growth factors derived from whey protein, which is a dairy protein, targeting 2 immune disorders:   psoriasis and inflammatory bowel disease.

Advitech Inc. (AVI-TSXV)

CURRENT ISSUE    |   COVER ARCHIVES    |       INDEX      |    CONTACT    |    FINANCIALS    |     MARKETING SERVICES   |    HOME PAGE

CEOCFO-Members Login
Become A Member!

This is a printer friendly page!

Advitech and its partners have introduced their Dermylex™ nutraceutical product for the management of psoriasis symptoms to clinics, drug stores and dermatologists throughout the United States and Canada.   France will follow at the end of 2006.

Healthcare
Biotechnology
(AVI-TSXV)

Advitech Inc.




Renaud Beauchesne
President and CEO

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
May 18, 2006

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“Yes but we have chosen to go with a more rapid path to sales and marketing; so we have chosen to go the nutraceutical path rather than the pharmaceutical one. We are a natural product, compared to a pharma product; this product has demonstrated its efficacy and its safety profile. We have done 2 clinical studies one was done in 2004, which was an open label study, meaning that there were no placebos involved in the study. In 2005, we did a double blind placebo controlled study, a randomized study on 84 patients. That means that we compared our product with a placebo and with this study we have shown that the product was having efficacy for light to moderate psoriasis. There were no side effects and because it was an oral product and not a topical product, the patients were interested because most of the products out there fore psoriasis is topical.” - Renaud Beauchesne